A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists
Citations Over TimeTop 24% of 1993 papers
Abstract
Starting from the structure of the novel nonpeptide AT1 receptor antagonist DuP 753 (losartan), a new series of potent antagonists was designed. In these compounds the central imidazole nucleus was replaced by the dihydroimidazol-4-one structure. The most active compounds had a spirocyclopentane or a spirocyclohexane ring in position 5. Like the imidazole series, the best substituents were the linear butyl chain in position 1 and the [2'-(tetrazol-5-yl)biphenylyl]methyl group in position 3. Antagonistic activity was assessed by the ability of the compounds to competitively inhibit [125I]AII binding to the AT1 subtype receptor and to antagonize AII-induced contractions in rabbit aorta rings. The most active compounds had IC50 values in the nanomolar range. In conscious rats, compounds 4 and 21 antagonized the AII pressor response when administered orally. Compound 21 (SR 47436) was the most active; it was recently shown to also be active in cynomolgus monkeys both intravenously and orally. This molecule is now undergoing clinical trials for the treatment of hypertension.
Related Papers
- → An Analysis of Citation pattern of Allelopathy Journal : A Case study(2006)
- A Research on Citation Standard(2013)
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → Citation Managers(1998)
- → Citation Form in Transition: The ALWD Citation Manual(2000)